Shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) have been given a consensus rating of "Moderate Buy" by the ten brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $16.90.
A number of research firms have recently weighed in on ROIV. Bank of America increased their target price on shares of Roivant Sciences from $11.00 to $12.00 and gave the company a "neutral" rating in a research report on Tuesday, January 2nd. Truist Financial restated a "buy" rating and set a $23.00 price target on shares of Roivant Sciences in a research note on Monday, March 25th. Deutsche Bank Aktiengesellschaft upped their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Wednesday, April 3rd. TheStreet upgraded shares of Roivant Sciences from a "d" rating to a "c+" rating in a research note on Tuesday, February 13th. Finally, Piper Sandler initiated coverage on shares of Roivant Sciences in a research note on Friday, January 5th. They set an "overweight" rating and a $20.00 price target on the stock.
Read Our Latest Report on Roivant Sciences
Insiders Place Their Bets
In other news, COO Eric Venker sold 96,950 shares of the firm's stock in a transaction on Friday, February 9th. The shares were sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the sale, the chief operating officer now owns 532,207 shares in the company, valued at approximately $5,811,700.44. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 4.60% of the company's stock.
Institutional Trading of Roivant Sciences
Institutional investors and hedge funds have recently made changes to their positions in the stock. Citigroup Inc. raised its position in shares of Roivant Sciences by 45.6% during the 3rd quarter. Citigroup Inc. now owns 326,431 shares of the company's stock valued at $3,813,000 after buying an additional 102,279 shares in the last quarter. Morgan Stanley raised its position in shares of Roivant Sciences by 48.7% during the 3rd quarter. Morgan Stanley now owns 19,311,631 shares of the company's stock valued at $225,560,000 after buying an additional 6,324,915 shares in the last quarter. Deerfield Management Company L.P. Series C grew its holdings in shares of Roivant Sciences by 18.4% during the 3rd quarter. Deerfield Management Company L.P. Series C now owns 1,604,487 shares of the company's stock valued at $18,740,000 after purchasing an additional 249,513 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Roivant Sciences during the 3rd quarter valued at $4,200,000. Finally, Corton Capital Inc. grew its holdings in shares of Roivant Sciences by 87.2% during the 3rd quarter. Corton Capital Inc. now owns 27,236 shares of the company's stock valued at $318,000 after purchasing an additional 12,685 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.
Roivant Sciences Stock Performance
Shares of Roivant Sciences stock traded up $0.15 on Friday, reaching $11.03. 3,109,700 shares of the company traded hands, compared to its average volume of 6,612,257. Roivant Sciences has a 52 week low of $8.06 and a 52 week high of $13.24. The company has a 50 day moving average of $10.92 and a 200 day moving average of $10.37. The firm has a market capitalization of $8.89 billion, a PE ratio of 2.12 and a beta of 1.34. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its earnings results on Tuesday, February 13th. The company reported ($0.26) earnings per share for the quarter, beating analysts' consensus estimates of ($0.33) by $0.07. Roivant Sciences had a net margin of 3,624.14% and a negative return on equity of 33.38%. The firm had revenue of $37.14 million during the quarter, compared to the consensus estimate of $30.72 million. Equities analysts forecast that Roivant Sciences will post -1.36 earnings per share for the current year.
About Roivant Sciences
(
Get Free ReportRoivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Read More
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.
Get This Free Report
